$0.53
7.91% yesterday
Nasdaq, Nov 15, 09:49 pm CET
ISIN
US28623U1016
Symbol
ELEV
Sector
Industry

Elevation Oncology Inc Stock price

$0.53
+0.01 2.41% 1M
-3.20 85.75% 6M
-0.01 1.02% YTD
+0.07 15.04% 1Y
-7.11 93.04% 3Y
-10.91 95.35% 5Y
-10.91 95.35% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.05 8.41%
ISIN
US28623U1016
Symbol
ELEV
Sector
Industry

Key metrics

Market capitalization $31.42m
Enterprise Value $-40.63m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 0.45
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-42.01m
Cash position $103.07m
EPS (TTM) EPS $-0.81
P/E forward negative
Short interest 11.09%
Show more

Is Elevation Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Elevation Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Elevation Oncology Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Elevation Oncology Inc forecast:

Buy
100%

Financial data from Elevation Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.03 0.03
25% 25%
-
-0.03 -0.03
25% 25%
-
- Selling and Administrative Expenses 15 15
2% 2%
-
- Research and Development Expense 27 27
24% 24%
-
-42 -42
18% 18%
-
- Depreciation and Amortization 0.03 0.03
25% 25%
-
EBIT (Operating Income) EBIT -42 -42
18% 18%
-
Net Profit -42 -42
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about Elevation Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Elevation Oncology Inc Stock News

Neutral
PRNewsWire
10 days ago
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to present preclinical data on the combination potential of EO-3021 with ...
Positive
GuruFocus
about one month ago
On September 30, 2024, Empery Asset Management, LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 4,000,000 shares of Elevation Oncology Inc (ELEV, Financial). This transaction, executed at a price of $0.5999 per share, represents a notable increase in the firm's stake in the biotechnology company.
Neutral
PRNewsWire
about 2 months ago
BOSTON , Sept. 23, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differe...
More Elevation Oncology Inc News

Company Profile

Elevation Oncology, Inc. operates as a precision oncology company. It focuses on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in New York, NY.

Head office United States
CEO Joseph Ferra
Employees 29
Founded 2019
Website www.elevationoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today